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E256, 1998.—The synthetic flavonoid EMD-49209 is a potent
inhibitor of the in vivo and in vitro binding of thyroxine (T4) to
transthyretin (TTR). We studied the distribution of 125I-
labeled EMD-49209 in maternal tissues, intestinal contents,
and fetal tissues in rats that were 20 days pregnant (from 1 to
24 h after intravenous injection). The percent dose of EMD
decreased quickly with time. In maternal brain no radioactive
flavonoid could be detected. EMD was excreted very rapidly
from the intestines. In the fetal compartment the percent
dose of EMD increased with time; after 24 h it contained 17%
of the EMD. The flavonoid was found in all fetal tissues
investigated and also in the fetal brain. Because TTR concen-
trations are high in the fetal rat, especially in the brain, the
transfer of flavonoid to the fetal brain might be linked to TTR
expression. The presence of flavonoid in the fetal brain raises
the possibility of an essential interference of flavonoids with
the availablity of T4 in the fetal compartment.
thyroid hormones; goitrogen
NATURAL FLAVONOIDS, which are plant pigments found
in edible plants, contribute to our normal diet. Earlier
studies have indicated that flavonoids are able to
induce goiter (13, 14). Together with this increase in the
weight of the thyroid, a decrease in iodide organifica-
tion was found. Recently it was shown that flavonoids,
as constituents of one of the widely consumed African
millet species, are the cause of goiter (11, 22). Next to
the high intake of millet there is also iodine deficiency
in these areas, but no correlations have been found
among goiter incidence, the individual iodine intake,
and urinary iodine excretion. A connection among
iodine, thyroid hormone availability for tissues, and
natural (11, 13, 14, 22) as well as synthetic flavonoids
(5, 15, 20, 24, 25) has been discussed. Synthetic flavo-
noids have proven to be a valuable tool for studying
thyroid hormone metabolism in vitro and in vivo. These
flavonoids were developed by molecular drug design as
thyroxine (T4) analogs due to their capacity to inhibit T4
binding to transthyretin (TTR) and to block T4 deiodin-
ation by the type I 58-deiodinase enzyme in vitro (6, 7,
12, 28). These flavonoids do not bind to albumin or
thyroid hormone-binding globulin (8, 16, 27). The syn-
thetic flavonoid 3-methyl-48,6-dihydroxy-38,58-diiodo-
flavone (EMD-49209) has been shown to enter tissues
and is eliminated and excreted very quickly (26).
As in humans (2, 10), thyroid hormones of maternal
origin are found in fetal rat tissues before the onset of
fetal thyroid function (9, 17–19) and are at present
believed to play a role in both early development (3, 21)
and protection against impaired fetal thyroid function
(4). TTR might be involved in the transfer of maternal
T4 to the fetal compartment. Because TTR is the
principal carrier protein in the fetus (23, 30), it is
important to know whether the transport of T4 espe-
cially to the fetal brain is influenced by TTR.
Recent data (20) showed an increase in free T4 in the
maternal and fetal circulations after administration of
EMD-21388 to rats, which is considered evidence that
the flavonoid crosses the placenta. To confirm this and
to investigate whether flavonoids also enter fetal tis-
sues and interfere with thyroid hormone metabolism,
we administered synthetic flavonoids to rats that were
20 days pregnant. In this study the 125I-labeled flavo-
noid EMD-49209 was given as an intravenous bolus
injection. At different time points, rats were bled via
the vena cava inferior and perfused with saline via the
cannula under ether anesthesia. The distribution and
elimination of the labeled flavonoid in the maternal and
fetal compartments were studied.
MATERIALS AND METHODS
Animals. The experiments were approved by the local
committee of animal care. One group of eight Wistar rats
(Central Proefdier Bedry´f/Wageningen Universiteit, Iffa
Credo, Brussels, Belgium) was used. The rats were individu-
ally housed at 22°C, with a 14:10-h light-dark cycle. They
were fed the American Institute of Nutrition Diet (1). To
prevent reutilization of free 125I from 125I-EMD-49209, the
rats received potassium iodide in their drinking water (10
mg/l) for 4–5 days. The addition of potassium iodide to the
drinking water does not affect thyroid function (29).
After two regular cycles the rats were mated. The day that
sperm appeared in the vaginal smear was taken as day 0 of
gestation. One week before the experiment all rats under-
went a surgical procedure; a cannula was inserted into the
right jugular vein and extended to the right atrium (24).
Materials. 125I-EMD-49209, containing ,20 µCi 125I/µg of
EMD-49209, was provided by Henning Berlin (Henning,
Germany) (26). Just before use the purity of the labeled
compound was checked by high-performance liquid chroma-
tography (HPLC) (26). There was ,0.1% iodide present, and
no other labeled metabolites could be detected.
The 400-µl bolus injection consisted of a tracer amount of
125I-EMD-49209 (7 µCi, equivalent to 350 ng of the flavonoid)
in saline, containing 5% normal rat serum, 0.3 U/ml heparin
(Organon, Tilburg, The Netherlands), and 0.4 mg/ml ticarcil-
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lin (Ticarpen; Beecham, Heppignies, Belgium). Ticarcillin is
used to prevent eventual bacterial infection and diminishes
nonenzymatic deiodination of the labeled compound (29);
heparin is used to keep the cannula patent.
Experimental design. At 1, 2, 3, 4, 8, 14.5, 18.5, and 24 h
after the bolus injection one pregnant rat was bled via the
vena cava inferior under ether anesthesia; the rats were then
perfused with saline via the cannula. Maternal tissues (blood,
liver, kidney, brain, and thyroid); six fetal units (fetus and
placenta in amnion sac), three from each uterine horn; and
several fetal tissues (blood, liver, brain, placenta, and carcass)
from all remaining fetuses (n 5 5–8) were removed, placed on
ice, homogenized, counted, extracted, and submitted to HPLC
to separate iodide, 125I-EMD-49209, and its metabolites as
described before in detail (24). In short, whole small tissues or
weighed samples were minced and homogenized at 0°C in
methanol-ammonia (90:10). To determine the flavonoid con-
tent a measured aliquot was taken of each homogenate and
the plasma; 125I was counted. The samples were extracted
with methanol-ammonia. The dried extracts were dissolved
in 0.1 ml 0.2 M ammonia and put through HPLC to separate
the flavonoid, iodide, and its metabolites. Analyses were
performed with HPLC using a reverse phase C8 10 3 0.4 cm
column (Chrompack, Middelburg, The Netherlands); the mo-
bile phase was 0.625 M ammonium acetate, pH 3.8, and
methanol (58:42, vol/vol). The fractions were collected and
counted in a gamma counter, and their radioactivity was
calculated as a percentage of the dose of 125I-EMD-49209
[corrected for trapped plasma (29)] and expressed per whole
organ. The maternal and fetal sides of the placentas were
analyzed separately.
The maternal intestines were divided into five segments:
three equal lengths of small intestine (I, II, and III), the
cecum, and colon; and the contents was taken out. Because
the animals were housed in metabolic cages, feces and urine
could be collected separately. All of these radioactivity mea-
surements were calculated as percent dose of 125I.
To check that the injected 125I-EMD-49209 was present in
the intact form and no unknown metabolites were present,
Table 1. Distribution of 125I-EMD-49209 radioactivity
as percentage of dose of 125I-EMD-49209 in maternal
tissues (per whole organ) and fetal compartment
1–24 h after bolus injection
Hours 1 2 3 4 8.5 14.5 18 24
Blood 54 45 33 28 13.7 6.5 3.6 2.7
Liver 6 6 4 3 1.3 0.5 0.4 0.3
Brain 0 0 0 0 0 0 0 0
The rest 18 24 24 22 15 15 5 7
Fetal comp 6 6 9 12 15 16 17 17
No. fetuses 14 13 14 11 12 13 12 11
For blood, liver, brain, and residual tissues (the rest), and fetal
compartment (fetal comp) percent dose is given as 125I-EMD-49209.
Residual tissues are all organs together except blood, liver, brain,
fetal compartment, and intestines plus content. Fetal compartment
consists of total number of fetal units per dam.
Fig. 1. Percent dose of 125I-EMD-49209 in several fetal tissues (blood,
brain, liver, carcass, total placenta), calculated as mean tissue values
multiplied by number of fetuses per dam per time period. Data were
analyzed by regression analysis, with time as independent parameter
and represented as best fit, R2, and P values. Blood and tissues were
extracted; extracts were submitted to high-performance liquid chro-
matography to separate EMD-49209, iodide, and its eventual metabo-
lites. Amount of iodide found in samples ranged between 2 and 8%;
metabolites were not detected. Fetal and maternal placenta are
presented as whole placenta.
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the label was added as a spike to the fetal plasma and
submitted to HPLC. With the exception of free iodide (,0.1%)
no other radioactive metabolites were detected. The extrac-
tion efficiency for 125I activity from all tissues was higher than
95%.
The computer program Kaleidograph for MacIntosh was
used for least squares nonlinear curve-fit analysis; it was
developed by Abelbeck Software and published by Synergy
Software.
RESULTS
In maternal blood there is a fast decrease in percent
dose 125I-EMD-49209 with time; in contrast, after 1 h
delay there is a gradual increase in the percent dose
flavonoid in fetal blood.
In Table 1 the percent dose 125I-EMD-49209 in mater-
nal blood, liver, brain, and the residual tissues is given
according to time. The residual tissues include all
organs and tissues together except blood, liver, brain,
and intestinal contents; muscle and skin accounted for
most of the radioactivity (about 10% each) of the
residual tissues. There is a decrease in percent dose
125I-EMD-49209 in maternal blood, liver, and the re-
sidual tissues, whereas there is an increase in percent
dose 125I-EMD-49209 in the total fetal compartment
with time. No flavonoid could be detected in the mater-
nal brain. Thyroidal uptake of the flavonoid was below
the detection limit. At 24 h most of the flavonoid
(60–70%) had been eliminated from tissues and plasma
and excreted via feces and urine (data not shown).
Figure 1 shows the increase in the percent dose
125I-EMD-49209 in fetal tissues, blood, brain, liver, and
carcass with time, presented together with the best fit,
R2, and P values. For the total placenta a decrease in
the percent dose of 125I-EMD-49209 was found.
DISCUSSION
The disappearance of the flavonoid from maternal
blood was comparable to the disappearance from the
blood of nonpregnant rats; the decrease in radioactivity
in maternal tissues and increase in the radioactivity in
intestinal content were also comparable (26). As shown
previously, the intact flavonoid or its metabolite does
not cross the blood-brain barrier in the adult rat (26).
This finding indicates that flavonoids might affect
thyroid hormone transfer to the brain via either the
blood-brain or the blood-choriod plexus-cerebrospinal
fluid barrier without being transported themselves by
TTR or other carriers (5, 27).
Our data indicate that the flavonoid crosses the
placenta and enters fetal tissues. The increase in the
flavonoid concentration in fetal tissues is striking.
Twenty-four hours after injection of the labeled com-
pound, 60–70% of it had already left the maternal body,
whereas about 17% of the initial dose of 125I-EMD-
49209 was still present in the fetal compartment, i.e.,
1.2–1.5% per fetus, indicating a relative accumulation
in the fetal rat compared with the mother. We have
shown that this synthetic flavonoid can reach the fetal
brain, in contrast to the maternal brain. In some fetal
tissues the flavonoid concentration was even higher
than in maternal tissues. Thus it seems that there is a
transfer of the flavonoid to the fetal compartment. The
question of whether this is caused by the large amount
of TTR in the fetal compartment has yet to be answered
(23, 30).
Synthetic flavonoids have been shown to displace T4
from TTR (5, 15, 25). TTR is the principal high-affinity
thyroid hormone carrier protein in the fetal rat. After
birth the TTR level decreases to nearly zero, but later it
increases again to adult levels (23, 30). Because the
flavonoid is present in the fetus, it is of importance to
realize that these flavonoids might interfere with T4
binding to TTR and thus might influence T4 availability
in tissues during a period when the hormone is very
important for fetal development (20). An essential
question still remains, namely, are these effects of a
synthetic flavonoid representative of those of natural
flavonoids that are common in our diet?
In conclusion, synthetic flavonoids cross the placenta
and enter fetal tissues, where they reach higher concen-
trations than in the tissues of the mother. It is tempting
to speculate that the fact that flavonoids reach the fetal
compartments, including the brain, implies that the
availability of thyroid hormones could be restricted in
fetal tissues. If transfer for natural flavonoids that act
as goitrogens (11, 22) also occurs, it is important to
realize that fetal development could be impaired by the
intake of these flavonoids that are part of the daily diet;
this is particularly true if there is also severe or
moderate iodine deficiency, which unfortunately is still
true in a large part of the world.
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